BR112021000515A2 - Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido. - Google Patents

Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido. Download PDF

Info

Publication number
BR112021000515A2
BR112021000515A2 BR112021000515-3A BR112021000515A BR112021000515A2 BR 112021000515 A2 BR112021000515 A2 BR 112021000515A2 BR 112021000515 A BR112021000515 A BR 112021000515A BR 112021000515 A2 BR112021000515 A2 BR 112021000515A2
Authority
BR
Brazil
Prior art keywords
compound
fact
methyl
tablet
amino
Prior art date
Application number
BR112021000515-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Kevin Michael Short
Maria De Los Angeles Estiarte-Martinez
David Ben KITA
Nilantha Sudath Sirisoma
Original Assignee
Verseon International Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseon International Corporation filed Critical Verseon International Corporation
Publication of BR112021000515A2 publication Critical patent/BR112021000515A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021000515-3A 2018-07-13 2019-07-12 Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido. BR112021000515A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697817P 2018-07-13 2018-07-13
US62/697817 2018-07-13
PCT/US2019/041699 WO2020014669A1 (en) 2018-07-13 2019-07-12 Thrombin inhibitors, formulations, and uses thereof

Publications (1)

Publication Number Publication Date
BR112021000515A2 true BR112021000515A2 (pt) 2021-04-06

Family

ID=67470750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000515-3A BR112021000515A2 (pt) 2018-07-13 2019-07-12 Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido.

Country Status (13)

Country Link
US (1) US11865110B2 (cg-RX-API-DMAC7.html)
EP (1) EP3820564B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021531338A (cg-RX-API-DMAC7.html)
KR (1) KR20210080347A (cg-RX-API-DMAC7.html)
CN (1) CN113164765B (cg-RX-API-DMAC7.html)
AU (1) AU2019300161B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000515A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106359A1 (cg-RX-API-DMAC7.html)
IL (1) IL280078B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000472A (cg-RX-API-DMAC7.html)
SG (1) SG11202100247WA (cg-RX-API-DMAC7.html)
WO (1) WO2020014669A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100955B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116735514B (zh) * 2023-08-11 2023-11-03 昆明理工大学 纳米酶结合液液微萃取快速检测天麻硫熏标志物的方法
WO2025184627A1 (en) * 2024-03-01 2025-09-04 Cadrenal Therapeutics, Inc. Method for preventing coagulation in patients with implanted cardiac devices

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5579843A (en) 1994-08-16 1996-12-03 Loitherstein; Joel S. Resilient spider for well installation
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SI21097A (sl) 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP2009543842A (ja) 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
CA2734804A1 (en) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012500244A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍療法におけるダビガトラン
JP2012500245A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経皮的インターベンション心臓カテーテル法のためのダビガトラン
DK2968297T3 (en) * 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物

Also Published As

Publication number Publication date
JP2021531338A (ja) 2021-11-18
KR20210080347A (ko) 2021-06-30
EP3820564B1 (en) 2026-07-08
JP2025098029A (ja) 2025-07-01
CN113164765B (zh) 2026-03-20
IL280078B2 (en) 2024-04-01
US20210315877A1 (en) 2021-10-14
SG11202100247WA (en) 2021-02-25
ZA202100955B (en) 2023-10-25
CN113164765A (zh) 2021-07-23
EP3820564A1 (en) 2021-05-19
CA3106359A1 (en) 2020-01-16
IL280078A (en) 2021-03-01
WO2020014669A1 (en) 2020-01-16
US11865110B2 (en) 2024-01-09
IL280078B1 (en) 2023-12-01
AU2019300161A1 (en) 2021-02-25
AU2019300161B2 (en) 2025-05-22
MX2021000472A (es) 2021-06-23

Similar Documents

Publication Publication Date Title
AU2017225000B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
JP7627974B2 (ja) Cdk7キナーゼ阻害剤として使用される化合物およびその適用
KR102113960B1 (ko) 트롬빈 억제제로서의 다중치환된 방향족 화합물
JP2020143112A (ja) セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
JP6236445B2 (ja) 組織トランスグルタミナーゼ阻害剤としてのピリジノン誘導体
KR20050100655A (ko) 티에노〔2,3-c〕피리딘 유도체를 함유하는 약제학적조성물 및 그의 용도
JP2025098029A (ja) トロンビン阻害薬、製剤、及びそれらの使用
HUE028426T2 (en) Isothiazolopyridinones for (inter alia) treating cystic fibrosis
KR20170095845A (ko) 디히드로인돌리지논 유도체
AU2014238478B2 (en) Halogenopyrazoles as inhibitors of thrombin
TW201738221A (zh) 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
TW202412778A (zh) 一種脯氨醯羥化酶抑制劑及其用途
JPS60243074A (ja) 4−フエニルフタラジン誘導体

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]